XTLB XTL Biopharmaceuticals ADRs

XTL Biopharmaceuticals Ltd is engaged in the acquisition & development of pharmaceutical drugs for the treatment of unmet medical needs, currently for the treatment of schizophrenia and Hepatitis C. It has also developed a home therapeutic device. This is an ADR of a company whose stock trades outside of the U.S. as the symbol IT:XTLB.

$1.63  -0.03 (-1.81%)
As of 08/05/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Israel
Country of incorporation:  Israel
IPO date:  02/18/2014
Outstanding shares:  5,449,062
Average volume:  4,578
Market cap:   $9,045,443
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.79
PS ratio:   0.00
Return on equity:   18.86%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy